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Abstract
Background: Patients with severe traumatic brain injury (TBI) are at risk of the development of acute respiratory
distress syndrome (ARDS). TBI and ARDS pathophysiologic mechanisms are known to independently involve
significant inflammatory responses. The literature on the association between plasma inflammatory cytokines and
ARDS in patients with TBI is sparse.
Methods: The study was a secondary analysis of the safety of a randomized trial of erythropoietin and transfusion
threshold in patients with severe TBI. Inflammatory markers within the first 24 hours after injury were compared in
patients who developed ARDS and patients without ARDS, using Cox proportional hazards models.
Results: There were 200 patients enrolled in the study. The majority of plasma and cerebrospinal fluid (CSF) cytokine
levels were obtained within 6 hours. Plasma proinflammatory markers IL-6 and IL-8 and anti-inflammatory marker IL-10
were associated with the development of ARDS (adjusted hazard ratio (HR) = 1.55, confidence interval (CI) = 1.14, 2.11,
P = 0.005 for IL-6; adjusted HR = 1.32, CI = 1.10, 1.59, P = 0.003 for IL-8).
Conclusion: Plasma markers of IL-6, IL-8, and IL-10 are associated with ARDS in patients with severe TBI.
Trial registration: NCT00313716 registered 4/2006
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Background
Severe head injury is associated with an early inflamma-
tory response of which proinflammatory and anti-
inflammatory cytokines are critical mediators of neuro-
inflammation [1–4]. The extent of brain injury is
determined by the severity of the primary mechanical in-
jury and the consequences of the secondary biomolecular
injury patterns [1–8]. Proinflammatory markers but not
anti-inflammatory markers have been found to be upregu-
lated in serum from patients with TBI [9]. Some inflam-
matory markers such as IL-6 have been reported to be a
possible predictor of elevated intracranial pressure (ICP)
in patients with isolated TBI [10]. These reports support
an inflammatory component to the pathophysiology of
severe TBI.
Acute respiratory distress syndrome (ARDS) is known to
involve an intense proinflammatory and anti-inflammatory
response in the lungs as demonstrated in numerous studies
[11–14]. Decreased IL-10 in bronchoalveolar lavage fluid
has been associated with mortality in patients with ARDS
[15]. Although there is a clear relationship between inflam-
matory mediators and ARDS, elevated plasma cytokines
have not been shown to be associated with ARDS in at-risk
medical patients [16, 17]. None of these studies included
patients with TBI.
Patients with severe TBI have high mortality and ARDS
is recognized as one of the significant contributors to in-
patient mortality and prolonged mechanical ventilation.
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Secondary injury may involve the development of systemic
inflammatory response syndrome (SIRS), ARDS, multiple
organ dysfunction syndrome, or sepsis [18–20]. Recogniz-
ing that TBI and ARDS involve significant inflammatory
mediators and patients with severe TBI are at risk of
ARDS, we hypothesized that early proinflammatory and
anti-inflammatory cytokines may be associated with the
development of ARDS.
Methods
Primary hypothesis and outcomes
The objective of this study was to determine the association
between cytokine levels just after severe traumatic brain
injury and the risk of ARDS. The Berlin definition of ARDS
events was used [21], based on acute onset within 7 days,
bilateral pulmonary infiltrates consistent with pulmonary
edema, impaired oxygenation (partial pressure of oxygen
(PaO2)/inspired oxygen fraction (FiO2) ratio <300 mm
Hg), and impaired oxygenation not fully explained by
cardiac failure [21].
Study design
This is a secondary analysis of the ARDS safety outcome
from the erythropoietin randomized controlled trial. The
study design has been reported previously [22]. Briefly, par-
ticipants were randomly assigned to administration of
Table 1 Baseline clinical characteristics by incident
Characteristic Developed acute respiratory distress
syndrome (Berlin definition)
Did not develop acute respiratory distress
syndrome (Berlin definition)
P value
(n = 52) (n = 148)
Age (years), median (IQR) 29.0 (19.5) 30.0 (23.0) 0.87
Male sex, n (%) 50 (96.2) 123 (83.1) 0.03
Race, n (%)
black 8 (15.4) 35 (23.6) 0.44
white 16 (30.8) 32 (21.6)
Hispanic 27 (51.9) 76 (51.4)
Asian 1 (1.9) 5 (3.4)
Emergency room sum Glasgow Coma Scale
> 8 7 (13.5) 38 (25.7) 0.04
6–8 21 (40.4) 68 (45.9)
3–5 24 (46.2) 42 (28.4)
Emergency room sum Glasgow Coma Scale,
median (IQR)
6.0 (5.0) 7.0 (4.0) 0.02
Marshall classification on computed tomography
mild diffuse injury I–II 23 (44.2) 66 (44.6) 0.22
severe diffuse injury III–IV 16 (30.8) 30 (20.3)
mass lesion 13 (25.0) 52 (35.1)
Acute Physiology and Chronic Health
Evaluation II score, median (IQR)
24.0 (11.0) 19.0 (7.0) <0.001
Abbreviated Injury Severity Score, median (IQR) 32.0 (14.5) 28.0 (10.0) 0.01
Intracranial pressure (n = 197), median (IQR) 14.0 (12.0) 14.0 (12.0) 0.84
Mechanism of injury, n (%)
assault 7 (13.5) 15 (10.1) 0.93
fall/jump 7 (13.5) 20 (13.5)
motor vehicle 28 (53.8) 88 (59.5)
Motorcycle 9 (17.3) 22 (14.9)
Other 1 (1.9) 3 (2.0)
Surgery on admission, n (%) 14 (26.9) 57 (38.5) 0.18
Pre-hospital hypotension, n (%) 7 (13.5) 18 (12.2) 0.81
Pre-hospital hypoxia 16 (30.8) 23 (15.5) 0.02
Time (days) from injury to ALI, median (IQR) 3.0 (3.0)
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erythropoietin or placebo and to hemoglobin transfusion
thresholds of 7 or 10 g/dl in a 2 × 2 factorial design. Partici-
pants with a closed head injury who were not able to follow
commands after resuscitation and could be enrolled within
6 hours of injury were recruited from two level-1 trauma
centers. Patients were excluded if their Glasgow Coma
Scale (GCS) score was 3, and they had fixed and dilated pu-
pils, penetrating trauma, pregnancy, life-threatening sys-
temic injuries, or severe preexisting disease. Transfusion of
leuko-reduced packed red blood cells was used to maintain
the assigned hemoglobin threshold. Patients were enrolled
using the emergency consent exception when relatives were
not available for prospective consent. The study was ap-
proved by the local Institutional Review Boards (IRBs) at
participating institutions.
Cytokine and nitric oxide (NOx) measurements
Heparinized blood samples were collected, usually via a
radial artery catheter. The samples were centrifuged, ali-
quoted, and temporarily stored at –80 °C in an area ad-
jacent to the ICUs at the hospitals until they were
transferred to our laboratory at Baylor College of Medi-
cine for analysis. Both enrolling hospitals were adjacent
to Baylor and the samples were transferred on dry ice
from the freezer at the hospital to the freezer at Baylor
where they were kept until they were analyzed.
Cytokine measurements were performed using multi-
plex flow cytometric bead array analysis (Beckton Dickin-
son Cytometric Bead Array, Human Inflammation Kit,
San Jose, CA, USA) in the Cytometry and Cell Sorting
Core at Baylor College of Medicine. This method permits
the simultaneous measurement of six cytokines (IL-1β, IL-
6, IL-8, IL-12, TNFα, and IL-10) in a single sample. In this
study, we evaluated IL-1β, IL-6, IL-8, IL-12, TNFα, IL-10
and nitric oxide (NOx). The final products of NO oxida-
tion (nitrate (NO3-) and nitrite (NO2-)) were analyzed in
plasma samples that were ultra-filtered through a 30-kDa
molecular weight cutoff filter (Millipore Corporation, Bill-
eria, MA, USA), and then transferred to a plate to be ana-
lyzed using a Nitrate/Nitrite Fluorometric assay kit
(Cayman Chemical’s Company, Ann Harbor, MI, USA)
using an excitation wavelength of 360–365 nm and an
emission wavelength of 430 nm (Synergy 2 Multi-Mode
Microplate Reader Biotek Instruments, Inc).
Data analysis
Statistical analyses were performed using SAS version 9.3
(SAS Institute Inc) and R version 2.13.1 (R Foundation for
Statistical Computing) with two-sided statistical tests at a
0.05significance level. Baseline covariates considered were
transfusion threshold randomization group (<10 g/dl; <7 g/
dl); erythropoietin (EPO) randomization group (Epo1 or
Epo2 if randomized to the first or second erythropoietin
dosing regimens, respectively, versus placebo); pre-hospital
hypotension present; pre-hospital hypoxia present; age
(years); emergency room (ER) GCS-sum; Injury Severity
Score (ISS); number of unreactive pupils (one or two versus
none); ER computed tomography (CT) high risk; and intu-
bated in ER (versus ICU or in the field) at baseline. The first
measurement of cytokines within 24 hours after injury was
Fig. 1 a Distribution of time of plasma cytokine measurement after injury. b Distribution of time of cerebrospinal fluid cytokine measurement after injury
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used as the baseline value. Although some measurements
were not obtained before transfusion or before EPO admin-
istration, there was no difference in ALI/ARDS between the
intervention and control arms of the randomized trial [22].
The Wilcoxon rank sum test or Fisher’s exact test was
used to compare continuous and categorical variables, re-
spectively, among patients who did or did not develop
ARDS. Cox proportional hazards regression was used to
determine whether the cytokine values were associated
with an increased risk of ARDS, adjusted for baseline vari-
ables. Due to the large number of potential baseline vari-
ables and the relatively small number of ARDS events,
variables were selected to build a parsimonious model.
Lasso-penalized Cox [23] regression, with the penalty par-
ameter selected using fivefold cross-validation, was used
for selection of variables in addition to the transfusion
threshold randomization group and all baseline variables
that were significantly different among patients who did or
did not have an ARDS event. The lasso penalization has
better statistical properties than other common methods
for variable selection, such as forward or backward step-
wise selection, which tend to result in underestimation of
the standard errors of the coefficients. Censor time was de-
fined as 6 months after injury, date of hospital discharge,
death, or withdrawal, whichever occurred first. Spearman’s
rank correlation (rho) was used to assess the correlation
between the initial cytokine value and the category of
ARDS severity based on the Berlin definition of ARDS.
Results
A total of 200 patients were enrolled in the study of whom
between 173 and 195 (87–98 %) were included in the cyto-
kine analyses, as there were varying numbers of missing
values for each cytokine. Patients were excluded if they did
not have any cytokine values available within 24 hours of
injury or if they had an ARDS event on the first day, be-
cause we did not know whether the cytokine measurement
was obtained before or after the ARDS event. The baseline
clinical characteristics are presented in Table 1. There were
some significant differences in some baseline characteristics
between patients with and without ARDS, notably a signifi-
cant difference in gender (96.2 % male (50/52) vs. 83.1 %
(123/148), respectively, p = 0.03). The GCS sum score in
the ER (median = 6 vs. 7, p = 0.02), Acute Physiology and
Chronic Health Evaluation (APACHE) II score (24 vs. 19, p
<0.001), Abbreviated Injury Severity Score (median = 32 vs.
28, p = 0.01), and pre-hospital hypoxia (present in 30.8 % of
patients (16/52) vs. 15.5 % (23/148)), respectively. The ma-
jority (86 %) of plasma cytokines were collected within
6 hours of injury (Fig. 1a) and 48 % of CSF cytokines were
collected within 6 hours of injury (Fig. 1b).
Table 2 Comparison of plasma cytokines among patients who had or did not have ARDS
Cytokine Normal ranges (pg/mL) ARDS median (25th, 75th) (min–max) No ARDS median (25th, 75th) (min–max) P value
(n = 51) (n = 144)
IL-12p70 (n = 194) 0–6 3.9 (2.2, 5.9) (0.1–163.6) 3.8 (2.7, 5.4) (0.2–40.7) 0.882
IL-10 (n = 195) 0–18 14.5 (8.1, 34.8) (0.2–147.6) 10.0 (6.1, 18.6) (0.2–98.2) 0.008
IL-8 (n = 194) 0–5 158.1 (45.0, 284.0) (0.04–2504.0) 57.4 (26.0, 135.1) (0.1–7393.0) <0.001
IL-6 (n = 195) 0–5 568.2 (224.4, 2278.0) (5.9–18,950) 241.2 (92.7, 638.8) (3.0–21,330.0) <0.001
IL-1β (n = 195) 0–39 5.4 (3.1, 9.0) (0.1–54) 4.7 (3.2, 8.3) (0.1–142.8) 0.702
Nitric oxide (n = 193) Not available 1.7 (1.3, 2.5) (0.01– 14.8) 1.5 (1.0, 2.4) (0.01–7.3) 0.266
TNF-α (n = 195) 0–22 3.8 (1.8, 6.2) (0.1–38.8) 3.9 (3.2, 5.4) (0.3– 95.9) 0.743
Table 3 Comparison of cerebrospinal fluid cytokines among patients who did or did not have acute respiratory distress syndrome
(ARDS) and those who did not
Cytokine Normal ranges (pg/mL) ARDS median (25th, 75th) (min–max) No ARDS median (25th, 75th) (min–max) P value
(n = 45) (n = 129)
IL-12p70 (n = 173) 0–2 3.8 (2.3, 5.7) (0.1–54.4) 3.5 (0.9, 4.1) (0.1–45.9) 0.155
IL-10 (n = 174) 0–1.5 7.0 (4.3, 15.6) (0.2–78.4) 5.1 (3.5, 10.0) (0.2–303.7) 0.026
IL-8 (n = 173) 0–2 1203.0 (93.7, 4782.0) (3.9–32,570.0) 985.9 (72.6, 6792.0) (0.04–204,900) 0.716
IL-6 (n = 174) 0–1 1820.0 (233.3, 7083.0) (0.2–17,790.0) 609.4 (58.6, 2917.0) (0.2–76,370) 0.085
IL-1β (n = 174) 0–3 5.6 (3.7, 8.0) (0.1–74.6) 5.2 (3.5, 8.1) (0.1–82.4) 0.490
Nitric oxide (n = 172) Not available 0.5 (0.3, 0.9) (0.01–3.6) 0.5 (0.1, 0.7) (0.01–3.98) 0.198
TNF-α (n = 174) 0–2 4.2 (2.1, 6.3) (0.3–38.8) 3.8 (2.0, 4.3) (0.3–30.3) 0.179
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Table 4 Associations between each plasma cytokine and time to development of acute respiratory distress syndrome from Cox
regression analysis in erythropoietin study subjects with traumatic brain injury (unadjusted and adjusted analyses)
Unadjusted Adjusted model
Number HR 95 % CI P value HR 95 % CI P value
IL-12p70 194 1.03 0.74,0.14 0.88 1.18 0.82, 1.69 0.36
TT10 1.24 0.70, 2.19 0.46
ER sum GCS 0.86 0.76, 0.98 0.02
Pre-hospital hypoxia 1.71 0.88, 3.33 0.11
Male sex 4.97 1.17, 21.16 0.03
ISS 1.04 1.00, 1.07 0.03
Intubated in ER 1.51 0.72, 3.17 0.28
Pre-hospital hypotension 0.62 025, 1.56 0.31
Pupil unreactive (1–2 vs. 0) 0.65 0.35, 1.22 0.18
TNF-α 195 0.96 0.67,1.37 0.81 1.03 0.71, 1.51 0.85
TT10 1.17 0.067, 2.07 0.56
ISS 1.03 0.99, 1.07 0.05
Male sex 4.79 1.15, 20.06 0.03
ER sum GCS 0.86 0.76, 0.98 0.02
Pre-hospital hypoxia 1.78 0.92, 3.43 0.08
Pre-hospital hypotension 0.62 025, 1.54 0.30
Pupil unreactive (1–2 vs. 0) 0.67 0.36, 1.25 0.21
Intubated in ER 1.55 0.74, 3.25 0.25
IL-10 195 1.57 1.17,2.11 <0.01 1.66 1.22, 2.26 <0.01
TT10 1.21 0.69, 2.11 0.51
ER sum GCS 0.86 0.76, 0.98 0.02
Pre-hospital hypoxia 2.00 0.98, 3.73 0.06
Male sex 5.23 1.23, 22.29 0.03
ISS 1.03 0.99, 1.06 0.11
Pre-hospital hypotension 0.50 0.20, 1.23 0.13
Pupil unreactive (1–2 vs. 0) 0.56 0.30, 1.05 0.07
IL-6 195 1.30 1.11,1.52 <0.01 1.24 1.05, 1.49 0.01
TT10 1.14 0.65, 1.99 0.65
Pre-hospital hypoxia 1.64 0.85, 3.16 0.14
Male sex 4.75 1.13, 19.95 0.03
ER sum GCS 0.89 0.79, 1.01 0.06
ISS 1.02 0.99, 1.06 0.22
Intubated in ER 1.50 0.71, 3.18 0.29
Pre-hospital hypotension 0.52 0.21, 1.28 0.15
Pupil unreactive (1–2 vs. 0) 0.60 0.32, 1.12 0.11
IL-1β 195 0.98 0.73,1.30 0.87 0.98 0.73, 1.32 0.89
TT10 1.17 0.67, 2.05 0.58
ISS 1.03 1.00, 1.07 0.06
ER sum GCS 0.86 0.76, 0.98 0.02
Pre-hospital hypoxia 0.62 0.25, 1.55 0.09
Pupil unreactive (1–2 vs. 0) 0.67 0.36, 1.25 0.21
Male sex 4.75 1.13, 20.0 0.03
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Plasma and CSF cytokine levels by ARDS status are
presented in Tables 2 and 3. Median IL-6, IL-8, and IL-
10 (IL-6 = 568.2, IL-8 = 158.1, and IL-10 = 14.5 pg/mL)
in plasma from the ARDS group was significantly higher
than in the non-ARDS group (IL-6 = 241.2, IL_8 = 57.4,
and IL-10 = 10.0 pg/mL). In CSF, median IL-10 was 7.0
and 5.1 pg/mL in patients with and without ARDS, re-
spectively, with a p value of 0.026.
Cox proportional hazard ratios (HR) for time to ARDS
are shown in Tables 4 and 5. We observed 66 % higher risk
for each unit increase in plasma IL-10 (HR = 1.66, 95 % CI
= 1.22, 2.26, p = 0.001). Plasma IL-6 and IL-8 were associ-
ated with 24 % and 26 % higher risk, respectively, for each
unit increase in cytokine value (IL-6 adjusted HR = 1.24,
95 % CI = 1.05. 1.49, p = 0.012; IL-8 adjusted HR = 1.26,
95 % CI = 1.04, 1.49, p = 0.02). CSF IL-12 was associated
with 52 % increased risk for each unit increase (adjusted
HR= 1.52, 95 % CI = 1.05, 2.21, p = 0.03). CSF IL-10 was as-
sociated with 33 % increased risk for each unit increase and
was statistically significant (adjusted HR = 1.33, 95 % CI =
1.00, 1.76, p = 0.05). There were no significant differences
in other proinflammatory and anti-inflammatory markers
in either the plasma or CSF (Tables 2, 3, 4 and 5). There
was positive correlation between the initial plasma cytokine
value and the Berlin definition of ARDS by severity: for IL-
6 rho = 0.12, p < 0.001, for IL-8 rho = 0.14, p < 0.001, and
for IL-10 rho = 0.15, p < 0.001.
High tidal volume ventilator strategies are known to
induce volume trauma and barotrauma and low tidal
volume strategies may be protective in patients with
ARDS. The median initial tidal volume, i.e., prior to the
development of ARDS, was 8.52 mL/kg (25th–75th per-
centiles = 8.18–9.10) for patients who developed ARDS
(n = 35) and 9.02 mL/kg (25th–75th percentiles = 8.38–
9.76) for patients who did not develop ARDS (n = 93),
and this was statistically significantly different (p = 0.04).
Discussion
Acute respiratory distress syndrome is a well-described
complication in patients who survive an initial traumatic
insult. Inflammatory responses to TBI, both local and sys-
temic, are complex. Invading cells from the blood (e.g.,
leukocytes, monocytes and macrophages) and/or activated
resident cells (e.g., microglia) release a number of inflam-
matory molecules and free radicals that can contribute to
brain edema and worsen neurological outcome. Increased
serum and/or CSF concentrations of proinflammatory and
anti-inflammatory cytokines, chemokines, and acute phase
reactant proteins have been observed following TBI. The
importance of inflammation in the progression of TBI-
associated pathologic change has been the focus of nu-
merous studies [1, 24, 25]. More recently, the expression
of these factors has been appreciated as a potential marker
Table 4 Associations between each plasma cytokine and time to development of acute respiratory distress syndrome from Cox
regression analysis in erythropoietin study subjects with traumatic brain injury (unadjusted and adjusted analyses) (Continued)
Intubated in ER 1.57 0.74, 3.30 0.24
Pre-hospital hypotension 0.62 0.25, 1.55 0.31
IL-8 194 1.33 1.11,1.59 <0.01 1.26 1.04, 1.53 0.02
TT10 1.04 0.58, 1.87 0.89
ISS 1.02 0.98, 10.5 0.62
ER sum GCS 0.90 0.80, 10.2 0.10
Pre-hospital hypoxia 1.94 1.01, 3.74 0.05
Pupil unreactive (1–2 vs. 0) 0.61 0.33, 1.15 0.12
Male Sex 4.20 1.01, 17.53 0.05
Pre-hospital hypotension 0.55 0.22, 1.35 0.19
NOx 193 1.64 0.90,3.00 0.11 1.60 0.89, 2.90 0.12
TT10 1.12 0.64, 1.97 0.69
ISS 1.03 1.00, 1.06 0.06
ER sum GCS 0.91 0.81, 1.03 0.13
Pre-hospital hypotension 0.56 0.22, 1.41 0.22
Pre-hospital hypotension 1.84 0.95, 3.56 0.07
Male sex 4.73 1.14, 19.62 0.03
Variables considered for adjustment included age, injury severity score (ISS), emergency room (ER) sum Glasgow Coma Scale (GCS), unreactive pupils, emergency
room computer tomography indicating high risk, pre-hospital hypotension, pre-hospital hypoxia, intubated in the ER, transfusion threshold, and each baseline
cytokine level. Cytokine level, transfusion threshold, pre-hospital hypoxia, ER sum GCS, sex, and ISS were forced into the adjusted model. HR hazard ratio, IL-12p70
interleukin-12 p70, TNF-α tumor necrosis factor alpha, IL-10 interleukin-10, IL-6 interleukin-6, IL-1β interleukin-1 beta, IL-8 interleukin-8, NOx nitric oxide, TT10
transfusion threshold <10 g/dL
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Table 5 Associations between each cytokine measured in cerebrospinal fluid and time to development of acute respiratory
distress syndrome from Cox regression analysis in erythropoietin study subjects with traumatic brain injury (unadjusted and
adjusted analyses)
Unadjusted Adjusted model
Number HR 95 % CI P value HR 95 % CI P value
IL-12p70 173 1.36 0.94, 1.95 0.10 1.52 1.04, 2.21 0.03
TT10 1.12 0.62, 2.04 0.69
Pre-hospital hypoxia 1.38 0.68, 2.79 0.38
Male sex 8.69 1.17, 64.53 0.03
ER sum GCS 0.90 0.79, 1.03 0.11
ISS 1.04 1.00, 1.07 0.04
TNF-α 174 1.22 0.83, 1.80 0.32 1.43 0.97, 2.14 0.08
TT10 1.08 0.60, 1.95 0.80
Pre-hospital hypoxia 1.27 0.63, 2.58 0.51
Male sex 10.40 1.38, 78.61 0.02
ER sum GCS 0.86 0.75, 0.99 0.03
ISS 1.04 1.01, 1.08 0.02
IL-10 174 1.27 0.99, 1.64 0.06 1.33 1.00, 1.76 0.05
TT10 1.27 0.69, 2.35 0.43
Pre-hospital hypoxia 1.57 0.64, 0.79 0.20
Male sex 6.98 0.95, 51.31 0.06
ER sum GCS 0.87 0.76, 0.99 0.04
ISS 1.02 0.99, 1.05 0.18
IL-.6 174 1.09 0.97, 1.21 0.14 1.06 0.95, 1.19 0.28
TT10 1.06 0.59, 1.92 0.83
Pre-hospital hypoxia 1.41 0.70, 2.82 0.33
Male sex 7.60 1.04, 55.59 0.05*
ER sum GCS 0.91 0.81, 1.03 0.15
ISS 1.02 0.99, 1.06 0.14
IL-1β 174 1.05 0.77, 1.43 0.76 1.11 0.80, 1.54 0.54
TT10 0.91 0.60, 2.01 0.76
Pre-hospital hypoxia 1.30 0.64, 2.65 0.47
Male sex 9.25 1.24, 69.18 0.03
ER sum GCS 0.88 0.78, 1.01 0.06
ISS 1.04 1.00, 1.08 0.14
IL-8 173 1.02 0.92, 1.13 0.70 1.01 0.92, 1.12 0.81
TT10 1.11 0.61, 2.01 0.73
Pre-hospital hypoxia 1.42 0.70, 2.88 0.32
Male sex 7.68 1.05, 56.22 0.04
ER sum GCS 0.92 0.81, 1.04 0.19
ISS 1.03 0.99, 1.06 0.11
NOx 172 2.11 0.89, 0.502 .09 1.66 0.70, 3.97 0.25
TT10 1.17 0.64, 2.13 0.61
Pre-hospital hypoxia 1.39 0.67, 2.88 0.37
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of injury, and studies have been carried out to test
whether these factors correlate with outcome or can serve
as surrogate markers of treatment efficacy.
TBI biomarkers have primarily focused on prediction of
elevated intracranial pressure or mortality. Several bio-
markers have emerged as possible markers of significant
neurological injury, including s100B, IL-8, and ceruloplas-
min. There are no data on biomarkers that predict ARDS
in patients with severe TBI, despite incidence of 20–30 %
and high mortality. In two separate studies in the late
1990s [16, 17], Parsons and Pittet did not identify any
association with inflammatory cytokines in non-TBI in at-
risk patients with ARDS.
Our study is the first to identify correlation between
initial cytokines in patients with TBI and the develop-
ment of ARDS. Elevated plasma markers of proinflam-
matory cytokines IL-6 and IL-8 and anti-inflammatory
marker IL-10 may indicate the importance of an extra-
cranial inflammatory response in the development of
ARDS. CSF cytokines IL-12 and IL-10 were statistically
significant in a fully adjusted model for markers of sever-
ity of illness, which we report in Table 5. CSF IL-12 and
IL-10 are potentially correlated with ARDS in patients
with TBI, but is difficult to confidently interpret this re-
sult and we suggest the results be cautiously interpreted
and that additional studies may be required to confirm
these associations. Severe TBI likely induces an inflam-
matory response that is not limited to the brain and the
TBI-mediated systemic response is likely involved in the
development of ARDS, and may be quantifiable in the
plasma. This is particularly relevant clinically and in
research, as early plasma markers are easier to obtain
than CSF.
The majority of cytokine levels were drawn within
6 hours of injury. The time frame within which the cyto-
kines were measured suggests an inflammatory response
that is triggered from the initial intracranial injury. Inter-
estingly, elevated ICP, a known prognosticator of mortal-
ity and a marker of disease severity in patients with
severe TBI [26], and the Marshall CT classification of in-
jury were similar in the ARDS and non ARDS groups
and therefore did not impact the development of ARDS.
It is worth noting that other potential triggers of an in-
flammatory response were considered, including mech-
anical ventilation and transfusion. High tidal volume
mechanical ventilation is known to be deleterious and
contribute to ventilator-induced lung injury (VILI) [27,
28]. Patients with severe TBI frequently have elevated
ICP, which makes low tidal volume lung-protective ven-
tilation [29] and permissive hypercapnea challenging
strategies to employ. The tidal volume in our study
population was modest and below typical thresholds for
high tidal-volume ventilation. Ventilator strategy likely
did not contribute to the incidence of ARDS as there
was no difference between the two groups. Critical to
the design of the study was the randomization of pa-
tients to prespecified transfusion triggers. The baseline
cytokine values reflect the period before administration
of any blood products, and we have previously reported
[22] that there was no difference in the incidence of
ARDS between the intervention and control groups.
Physicians caring for patients with severe TBI should be
aware of the complex neuroinflammatory mechanisms
that are associated with ARDS in patients with TBI and
should consider strategies to minimize lung injury early
in the treatment algorithm in patients who survive the
initial injury.
Our study has several limitations worth acknowledg-
ing. The study is a retrospective and secondary analysis
of prospectively collected data on erythropoietin in se-
vere TBI. However, we feel this does not impact the re-
sults or strength of the study as the variables and
outcomes were selected and collected prospectively. The
cytokine measurements were single as opposed to se-
quential measurements. While sequential measurements
may provide additional information, we felt sequential
measurements would be more difficult to interpret and
could potentially be influenced by our primary interven-
tional study. Therefore, initial cytokine concentrations
were used for analysis. Our study protocol did not re-
quire lung-protective strategies in all patients. However,
there was no statistical difference in mean tidal volume
between our groups and we do not believe this contrib-
uted to the development of ARDS.
Table 5 Associations between each cytokine measured in cerebrospinal fluid and time to development of acute respiratory
distress syndrome from Cox regression analysis in erythropoietin study subjects with traumatic brain injury (unadjusted and
adjusted analyses) (Continued)
Male sex 6.76 0.91, 49.9 0.06
ER sum GCS 0.89 0.78, 1.02 0.09
ISS 1.02 0.99, 1.06 0.14
Variables considered for adjustment included age, injury severity score (ISS), enrollment sum Glasgow Coma Scale (GCS), unreactive pupils, emergency room (ER)
computed tomography indicating high risk, pre-hospital hypotension, pre-hospital hypoxia, intubated in the ER, transfusion threshold, and each baseline cytokine
level. Cytokine level, transfusion threshold, pre-hospital hypoxia, ER sum GCS, sex, and ISS were forced into the adjusted model. HR hazard ratio, IL-12p70
interleukin-12 p70, TNF-α tumor necrosis factor alpha, IL-10 interleukin-10, IL-6 interleukin-6, IL-1β interleukin-1 beta, IL-8 interleukin-8, NOx nitric oxide, TT10
transfusion threshold <10 g/dL
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Conclusion
Elevated plasma inflammatory markers IL-6, IL-8, and IL-
10 in the early phase of severe acute TBI are associated
with the development of ARDS. Additional studies to
validate these findings are needed.
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